Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Non Small Cell Lung Carcinoma NSCLC 1Lung Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 44Carboplatin 35Paclitaxel 27Specimen Handling 18Cyclophosphamide 16Capecitabine 16Magnetic Resonance Spectroscopy 14sacituzumab govitecan 13Gemcitabine 13Taxes 12Biopsy 12130-nm albumin-bound paclitaxel 11Albumin-Bound Paclitaxel 9Doxorubicin 8olaparib 7Nivolumab 7fludarabine 6Cisplatin 6eribulin 5atezolizumab 5Radiotherapy 5Docetaxel 5durvalumab 4Fulvestrant 4Epirubicin 4Drug Therapy 4Bevacizumab 4veliparib 3famitinib 3camrelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × CP protocol × 90 days × Clear all
NCT07610525 2026-05-28

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
200 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡